RxDoctor Payments Data

Deepa Nagaraja, MD

Nephrology · Pueblo, CONPI 1396009734

Payments from drug & device makers

$1,229in general payments, 2019–2025

Across 54 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$223
  • Otsuka America Pharmaceutical, Inc.$183
  • AbbVie$124
  • Travere Therapeutics, Inc.$93
  • Mallinckrodt Hospital Products Inc.$86
  • Novartis$81
  • plus $438 from 12 others

What the payments were for

  • Food & beverage$1,229100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,229 in reported general payments places this provider in the 55th percentile of 152 nephrology providers in Colorado.

See all nephrology providers in Colorado

Medicare billing

Part B allowed, 2024
$251,395
Medicare patients
206
Services billed
3,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide21$72,125
FarxigaDapagliflozin Propanediol30$35,943
LokelmaSodium Zirconium Cyclosilicate25$17,697
Sevelamer Carbonate41$11,379
Calcium Acetate33$5,155
Bumetanide33$1,128
Nifedipine ErNifedipine46$1,035
Labetalol Hcl14$925
Calcitriol43$711
Losartan Potassium55$645
Gentamicin Sulfate18$596
Lisinopril83$504
Amlodipine Besylate65$496
Promethazine Hcl20$396
Hydralazine Hcl27$279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$65$72,12521 claims
AstraZenecaFarxiga, Lokelma$223$53,63955 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 152 nephrology providers in Colorado.

Other nephrology in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →